Product
W0180
1 clinical trial
1 indication
Indication
Metastatic Solid TumorsClinical trial
Phase I Dose Escalation and Dose Expansion, International, Multicenter Study of W0180 as Single Agent and in Combination With Pembrolizumab (Anti-PD-1) in Adult Participants With Locally Advanced or Metastatic Solid TumorsStatus: Terminated, Estimated PCD: 2023-12-19